Targeting EBV-encoded products: Implications for drug development in EBV-associated diseases

Area of Science:

• Virology
• Oncology
• Pharmacology

Background:

• Epstein-Barr virus (EBV), a human gamma-herpesvirus, is linked to numerous cancers and public health issues globally.
• Existing treatments often target specific EBV-encoded proteins, but novel therapeutic strategies are needed.

Purpose of the Study:

• To review current drugs and biomolecules targeting Epstein-Barr virus (EBV) products.
• To summarize the mechanisms of action for these therapeutic agents.
• To provide insights for designing novel drugs against EBV-associated diseases.

Main Methods:

• Literature review of existing studies on EBV-targeting drugs.
• Analysis of drug mechanisms acting on EBV-encoded proteins (e.g., LMP1, EBNA1).
• Exploration of emerging vaccine, immunological, and cellular therapies.

Main Results:

• Several drugs, including Silvestrol, curcumin, and thymoquinone, target key EBV proteins like LMP1, LMP2, and EBNA1.
• These agents function by activating or inhibiting biomolecules, impacting cellular signaling pathways.
• Promising advancements in vaccines and immunotherapies for EBV are also noted.

Conclusions:

• Targeting EBV-encoded products with specific drugs offers a viable strategy for treating EBV-associated diseases.
• Understanding unique drug mechanisms can guide the development of more effective therapies.
• Further research into novel drugs, vaccines, and immunotherapies is crucial for combating EBV.